News | Cardio-oncology | September 28, 2016

Cardiac Risk a Factor When Considering Hormonal Therapy for Prostate Cancer

Decision analysis model study shows men with low-risk prostate cancer and history of heart attack may be harmed by adding hormone therapy to radiation therapy

prostate cancer, hormone therapy, cardiac risk factors, Yale Cancer Center study, ASTRO 2016

September 28, 2016 — In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. The findings were presented at the American Society for Radiation Oncology (ASTRO) meeting, Sept. 25-28 in Boston.

Hormone therapy is used for treatment of prostate cancer to block the production of androgens, or male sex hormones. Androgens are necessary for the growth and spread of prostate cancer cells. Hormone therapy suppresses the androgen production in the body and stops the spread and growth of prostate cancer cells.

This study used a previously published decision analysis model that compared quality-adjusted life years (QALYs) in men aged 50, 60 and 70 years who received radiation therapy and no hormone therapy for high-risk prostate cancer and their cardiac risk factors. The research team used data from the recently published EORTC 22991 trial to study men with intermediate-risk prostate cancer, randomized to either radiation therapy or radiation therapy and six months of hormone therapy.

Hormone therapy was associated with a net decrease of 0.3 – 0.4 QALYs in men with a prior history of heart attack. However, for all other men, hormone therapy improved QALYs (range 0.4 - 2.6). Younger men with fewer cardiac risk factors experienced the largest benefit from hormone therapy. Men at low risk for biochemical failure (≤8.7 percent at 5 years) did not benefit from hormone therapy. Further, the benefits of hormone therapy did not begin to manifest until after 7.3 years of follow-up.

“Patient age, cardiac risk, and disease recurrence risk should be considered when selecting candidates for hormone therapy in this patient population,” said Nataniel Lester-Coll, M.D., first author on the study and a resident in the Department of Therapeutic Radiology at Yale School of Medicine. “Men with a history of heart attack who are at very low risk for biochemical failure may be harmed by the addition of hormone therapy.”

For more information: www.astro.org

Related Content

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit
ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...